Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium sodium phosphosilicate + sodium monofluorophosphate is a therapeutic dental combination developed by GSK Consumer Healthcare for the management of dentin hypersensitivity and the prevention of dental caries. The formulation combines **calcium sodium phosphosilicate (CSPS)**, a bioactive glass material marketed under the brand name **NovaMin**, with **sodium monofluorophosphate (SMFP)**, a fluoride source. CSPS works by reacting with saliva to release calcium and phosphate ions, which form a resilient hydroxyapatite-like layer that physically occludes exposed dentin tubules, thereby blocking the hydrodynamic triggers of tooth sensitivity. Simultaneously, SMFP provides fluoride ions that promote enamel remineralization and enhance resistance to acid-induced demineralization (anticaries effect). This combination is widely utilized in specialized dentifrice products globally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium sodium phosphosilicate + sodium monofluorophosphate.